



Subscriber access provided by University of Sunderland

# Article

# Catch and Release Photosensitizers: Combining Dual Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers

Karan Arora, Mackenzie Herroon, Malik H. Al-Afyouni, Nicholas P. Toupin, Thomas N. Rohrabaugh, Jr., Lauren M. Loftus, Izabela Podgorski, Claudia Turro, and Jeremy J. Kodanko *J. Am. Chem. Soc.*, **Just Accepted Manuscript •** DOI: 10.1021/jacs.8b08853 • Publication Date (Web): 02 Oct 2018 Downloaded from http://pubs.acs.org on October 3, 2018

# Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

# Catch and Release Photosensitizers: Combining Dual Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers

Karan Arora,<sup>1</sup> Mackenzie Herroon,<sup>2</sup> Malik H. Al-Afyouni,<sup>3</sup> Nicholas P. Toupin,<sup>1</sup> Thomas N. Rohrabaugh, Jr.,<sup>3</sup> Lauren M. Loftus,<sup>3</sup> Izabela Podgorski,<sup>2,4\*</sup> Claudia Turro,<sup>3\*</sup> and Jeremy J. Kodanko<sup>1,4\*</sup>

<sup>1</sup> Department of Chemistry, Wayne State University, 5101 Cass Ave, Detroit, MI 48202
 <sup>2</sup>Department of Pharmacology, School of Medicine, Wayne State University, Detroit, Michigan 48201

<sup>3</sup>Department of Chemistry and Biochemistry, The Ohio State University, Columbus Ohio 43210, <sup>4</sup>Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201

#### Abstract

Dual action agents containing a cysteine protease inhibitor and Ru-based photosensitizer for photodynamic therapy (PDT) were designed, synthesized and validated in 2D culture and 3D functional imaging assays of triple-negative human breast cancer (TNBC). These combination agents deliver and release Ru-based PDT agents to tumor cells and cause cancer cell death upon irradiation with visible light, while at the same time inactivating cathespin B (CTSB), a cysteine protease strongly associated with invasive and metastatic behavior. In total five Ru-based complexes were synthesized with the formula [Ru(bpy)<sub>2</sub>(1)](O<sub>2</sub>CCF<sub>3</sub>)<sub>2</sub> (3), where bpy = 2,2'-

bipyridine and  $\mathbf{1} = a$  bipyridine-based epoxysuccinyl inhibitor, and  $[Ru(tpy)(NN)(2)](PF_6)_2$  where tpy = terpiridine, 2 = a pyridine-based epoxysuccinyl inhibitor, NN = 2,2'-bipyridine (4); 6,6'dimethyl-2,2'-bipyridine (5); benzo[*i*]dipyrido[3,2-*a*:2',3'-*c*]phenazine (6); 3.6dimethylbenzo[*i*]dipyrido[3,2-*a*:2',3'-*c*]phenazine (7). Compound 3 contains a  $Ru(bpy)_3$ fluorophore and was designed to track the subcellular localization of the conjugates, whereas compounds 4–7 were designed to undergo either photoactivated ligand dissociation and/or singlet oxygen generation. Photochemical studies confirmed that complexes 5 and 7 undergo photoactivated ligand dissociation, whereas 6 and 7 generate singlet oxygen. Inhibitors 1–7 all potently and irreversibly inhibit CTSB. Compounds 4-7 were evaluated against MDA-MB-231 TNBC and MCF-10A breast epithelial cells in 2D and 3D culture for effects on proteolysis and cell viability under dark and light conditions. Collectively, these data reveal that 4–7 potently inhibit dye-quenched (DQ) collagen degradation, whereas only compound 7 causes efficient cell death under light conditions, consistent with its ability to release a Ru(II)-based photosensitizer and to also generate  ${}^{1}O_{2}$ .

#### Introduction

Cysteine cathepsins are a family of 11 human cysteine proteases that are highly expressed in a variety of cancers.<sup>1-3</sup> Collectively, these enzymes contribute to tumor progression, growth, invasion, angiogenesis and metastasis. In addition to being found intracellularly in lysosomes, cysteine cathepsins are secreted and bind to the surface of cancer cells.<sup>3</sup> Activity-based probes (ABPs) that target cysteine cathepsins rapidly differentiate between normal and tumor tissue *in vivo*, allowing for visual imaging of cells left behind at the tumor margins after resection.<sup>4-11</sup> These results show that surface-bound cathepsins can be targeted to achieve selective delivery of agents

to the invasive edges of tumors.<sup>12</sup> Prodrug activation strategies that take advantage of proteolytic activity of pericellular cathepsin B have also shown promise, confirming that these enzymes are active at the surface of tumors.<sup>13-15</sup> Relative to this project, inhibitors of cysteine cathepsins have shown efficacy in preclinical models of cancer, including breast cancer.<sup>16-20</sup> Given the crucial role, secretion, and membrane association of cysteine cathepsins in cancer, designing inhibitor-drug conjugates that simultaneously block invasive behaviors and deliver drugs is an attractive approach. In addition to cancer cells, tumor-associated macrophages (TAMs) and stromal cells that express CTSB and contribute to invasiveness, but are difficult to kill with conventional approaches, can be targeted with CTSB inhibitors as delivery vehicles.<sup>21</sup> It is also important to note that TAMs play a critical role in breast cancer malignancy.<sup>22</sup>

Photodynamic therapy (PDT) is a clinically approved technique for the treatment of many cancers.<sup>23-33</sup> PDT is commonly used after tumor surgical resection to kill cancer cells that invade outside the margins and are left behind within the tumor cavity. It is a two-step process that involves uptake of a photosensitizer by cancer cells, followed by drug activation using low energy light, resulting in the generation of reactive oxygen species (ROS) that cause oxidative damage and cell death. The precision of PDT is dependent upon selective uptake of the photosensitizer by cancer cells, as well as and the region where irradiation occurs. Due to suboptimal tumor targeting and uptake of current PDT drugs, considerable efforts have been made to enhance PDT drug efficacy using standard drug delivery strategies.<sup>34</sup> However, in all of these approaches, the uptake of the photosensitizer into the cancer cell is a primary concern. In order for the PDT drug to do the most damage to cancer cells, it must be able to reach intracellular organelles, especially the mitochondria; generation of ROS at the cancer cell surface is not sufficient to achieve efficient cell killing.<sup>29</sup> In addition, subcellular localization can vary as a function of the method of conjugation

to the delivery agent. Importantly, none of the current delivery strategies for PDT drugs inhibit crucial activity in cancer. Instead these approaches rely on ligand-receptor interactions on the surface, which on their own show little anticancer activity.<sup>35-37</sup> Recently, researchers have taken advantage of high extracellular concentrations of proteases, including cysteine cathepsins, at tumor sites to effect the proteolytic release of PDT agents and other drugs.<sup>14,15</sup> While the strategy does provide an advantage in that multiple equivalents of drug can be released through the catalytic action of tumor-associated proteases, it does nothing to inactivate cathepsins and other proteases that are associated with invasiveness and metastatic behavior.

We chose a different strategy to achieve highly effective PDT, namely the use of Ru(II)based photosensitizers that are resistant to photobleaching, are water soluble, cell permeable and are known to accumulate within the mitochondria of cancer cells due to their lipophilic cationic nature.<sup>38</sup> Ruthenium complexes are a potent class of metallopharmaceuticals that have advanced to clinical trials (Figure 1).<sup>39-42</sup> Due to their rich photochemistry and resistance to photobleaching,<sup>43</sup> a common problem with current photosensitizers,<sup>44</sup> ruthenium complexes are undergoing active development as a new class of PDT drugs.<sup>45-48</sup> Most recently the PDT drug TLD-1433 advanced to Phase Ib clinical trials for the treatment of bladder cancer.<sup>49-51</sup> These complexes show attractive properties, including high stability and cell permeability,<sup>52,53</sup> low toxicity,<sup>54-57</sup> and higher light to dark ratios for cell killing than current PDT drugs. The Turro group recently developed hybrid complexes that show dual reactivity with low energy light, with high quantum yields observed for photoactivated ligand dissociation and ROS generation.<sup>58,59</sup> These ruthenium complexes provide a perfect lead for the development of highly efficacious agents with two mechanisms of action, where a ruthenium photosensitizer could be released, taken up by cells and activated with light to generate ROS at a tumor site (Figure 2). However, in order for these complexes to reach their full potential, methods for tumor-specific delivery must be developed.



Figure 1. Structures of ruthenium-based drugs



**Figure 2.** Dual therapeutic for tumor-specific delivery, cysteine cathepsin inhibition and cell death through generation of ROS

In this manuscript we describe the synthesis, biochemical and biological characterization of a dual action compound that potently inhibits CTSB and releases a Ru(II)-based photosensitizer upon irradiation with visible light. This complex includes a delivery vector that not only carries the Ru(II)-based photosensitizer to cancer and tumor-associated cells but also irreversibly inactivates CTSB. Our lead compound is a derivative of CA-074 and NS-134 (Figure 3), which are highly potent, selective and irreversible inhibitors of CTSB.<sup>60,61</sup> In addition to our lead dual-action compound, we synthesized four other Ru(II) conjugates that were used to test the role of the inhibitor, photoactivated release, and generation of  ${}^{1}O_{2}$  on compound efficacy, as well as the subcellular localization of the complexes. These complexes were evaluated in a 3D pathomimetic model of triple negative human breast cancer (TNBC) in order to probe the efficacy of our compounds in an environment that mimics the *in vivo* tumor microenvironment, including acidification of  ${}^{1}O_{2}$  are vital in achieving efficient cell death.



NS-134

Figure 3. Epoxysuccinyl-based inhibitors of CTSB

**Experimental Section** 

#### 

# **General Considerations**

NMR spectra were recorded on a Varian FT-NMR Mercury-400 MHz Spectrometer. Mass spectra were recorded on a Time-of-Flight Micromass LCT Premier XE Spectrometer. IR spectra were recorded on a Nicolet IS5 FT-IR spectrophotometer (thin film). UV-vis spectra were recorded on a Varian Cary 60 spectrophotometer. All reactions were performed under ambient atmosphere unless otherwise noted. Anaerobic reactions were performed by purging the reaction solutions with Ar or nitrogen.

#### Methods

**Stability Studies.** DMSO stock solutions of complexes 3–7 (10.0 µL, 40 mM) were added to individual wells on a clear microtiter plate containing 190 µL DMSO in the dark. Plates were loaded into a Tecan Infinite M200 Monochromator-based Modular Multi-function Microplate Reader preequilibrated at 25.0 °C and absorbance spectra were recorded every 4 h for 24 h. Similarly DMSO stock solutions of complexes 3–7 (40 mM) were diluted in cell growth media (phenol red-free Dulbecco's modified Eagle's cell growth medium (DMEM) supplemented with 10% FBS, 10mM HEPES, 100 U/ml penicillin-streptomycin, 25 mM PIPES, and acidified to pH 6.8) pre-equilibrated at 37 °C to A  $\approx$  1 (< 10% final concentration DMSO). Electronic absorption spectra were recorded every 4 h for 24 h at 37 °C (Fig. S58-67), respectively.

**Photochemistry**. Electronic absorption spectra were obtained using a Hewlett-Packard 8453 diode array spectrophotometer and luminescence was measured using a Horiba Fluoromax-4 spectrometer in  $1 \times 1$  cm quartz cuvettes. Luminescence decay traces were collected using an Edinburgh EPL-445 pulsed diode laser ( $\lambda = 444.4$  nm, pulse width = 84.4 ps) focused on a sample at 90° to an Edinburgh M300 emission monochromator and Bentham DH-00-Te PMT detector. Sample irradiation was performed using a 150 W Xe arc lamp (USHIO) in a MilliArc lamp housing

unit with an LPS-220 power supply and an LPS-221 igniter (PTI). The desired irradiation wavelengths were controlled by selecting the appropriate long pass (CVI Melles Griot) or bandpass (Thorlabs) filters. In general, the samples were irradiated in water (<5% methanol) or acetonitrile in a quartz cuvette. For photolysis experiments, electronic absorption spectra were recorded at various time points of irradiation. The ligand exchange quantum yields ( $\Phi_{LE}$ ) were determined by irradiating the samples in water or acetonitrile using a 500 nm band pass filter together with a 475 nm long pass filter. Electronic absorption spectra were recorded at early irradiation times (<10% conversion) during the quantum yield determination, and the rate of consumption of the reactant was determined from the slope of the line of a plot of the moles of reactant vs. irradiation time. The photon flux of the lamp was determined using potassium ferrioxalate as the chemical actinometer.<sup>62</sup> The quantum yield for ligand dissociation using 500 nm light was calculated as the rate of moles of reactant consumed divided by the photon flux and corrected for the mean fraction of light absorbed by the sample. The quantum yields for  ${}^{1}O_{2}$  production ( $\Phi_{\Delta}$ ) were measured using  $[Ru(bpy)_3]^{2+}$  as a standard, with  $\Phi_{\Delta} = 0.81$  in CH<sub>3</sub>OH, and 1,3-diphenylisobenzofuran (DPBF) as a <sup>1</sup>O<sub>2</sub> trap.<sup>63</sup> DPBF is emissive in CH<sub>3</sub>OH, and the resulting product from the reaction of DPBF with <sup>1</sup>O<sub>2</sub> is nonemissive. The absorbance values of samples in methanol were matched at the irradiation wavelength (A = 0.01 at 460 nm) in a  $1 \times 1$  cm quartz cuvette. The samples were irradiated in the sample compartment of the fluorimeter ( $\lambda_{irr} = 460$  nm) in the presence of 1.0  $\mu$ M DPBF, and the quenching of the DPBF emission ( $\lambda_{exc} = 405 \text{ nm}$ ;  $\lambda_{em} = 479 \text{ nm}$ ) was monitored as a function of irradiation time. The quantum yield was determined by comparing the rate of DPBF emission quenching for the sample with that obtained for the  $[Ru(bpy)_3]^{2+}$  standard. The emission quantum yield was measured using  $[Ru(bpy)_3]^{2+}$  in nitrogen sparged H<sub>2</sub>O as the reference ( $\Phi_{em} =$  $0.042).^{64}$ 

**Enzyme Inhibition**. Thermodynamic and kinetic parameters for inhibition of CTSB were determined as previously described.<sup>65</sup> Briefly, hydrolysis of Z-Arg-Arg-AMC to form the fluorophore AMC was monitored over time in the presence of compounds **1–7** (0–10 nM). Solutions of activated CTSB (25  $\mu$ L) were added via multichannel pipet to individual wells containing Z-Arg-Arg-AMC, inhibitor and buffer that were prepared in the dark. Plates were immediately loaded into a Tecan plate reader and formation of free AMC over time was determined using excitation (360 nm) and emission (430 nm) filters. The CTSB stock was diluted to 16 nM (4nM final concentration) in buffer solution (400 mM sodium acetate, 4 mM EDTA, pH 5.5) containing 8 mM DTT, and activated for 15 min at 37 °C. Inhibitors were prepared as <1% DMSO stock solutions in assay buffer (400 mM sodium acetate, 4 mM EDTA, 0.01% Triton-X 100, pH 5.5). The substrate Z-Arg-Arg-AMC in assay buffer (200  $\mu$ M, 50  $\mu$ L) was diluted to achieve a final concentration of 100  $\mu$ M. Data were fit to a two-step irreversible enzyme inhibition model using Dynafit as previously described.<sup>65</sup> Experiments were performed in triplicate; K<sub>i</sub>, k<sub>inact</sub> and k<sub>inact</sub>/K<sub>i</sub> values are averages of three runs and errors are standard deviations.

2D Cell Culture and Cytotoxicity Assays. MDA-MB-231, a well-studied human breast carcinoma line and MCF-10A, a normal breast epithelial line, were purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). MDA-MB-231 cells were cultured in DMEM supplemented with penicillin (10,000 U/mL), streptomycin (10 mg/mL) and 10% fetal bovine serum. MCF-10A cells were cultured in DMEM supplemented with 5% horse serum, EGF (20 ng/mL), hydrocortisone (0.5 mg/mL), insulin (10  $\mu$ g/mL), penicillin (10,000 U/mL), and streptomycin (10 mg/mL). Cells were incubated at 37°C and kept under 5% CO<sub>2</sub> atmosphere. Cells were cultured in 10 cm<sup>2</sup> cell-treated dishes from ThermoFisher Scientific. Cell media was replaced

48h after incubation and cells were removed from the plate and re-seeded 24–48 h after changing of the media.

For viability experiments cells were seeded at 5,000cells/well on 96-well plates in 100µL of the appropriate media. The plates were incubated for 16–18h. After incubation, the media was aspirated from each well and then the control wells were replaced with 100  $\mu$ L of fresh media while the treatment wells were filled with 100  $\mu$ L of media containing 4–7 (1–10  $\mu$ M). After addition of the treatment media, plates for irradiation (Light) were transferred to the incubator, while the plates which would not undergo irradiation were covered in aluminum foil and then transferred to the incubator (Dark). After a 4 h incubation period the Light plates were removed and irradiated with an Ealing 250W tungsten halogen lamp with an 8 amp 15V power supply for 20 min. The light beam was filtered through 10 cm of water and the distance between the light source and the plate was situated so that the entire plate could be irradiated evenly. After irradiation, the plates were incubated for an additional hour and were then irradiated for an additional 25 min. The plates were then incubated for 72 h. After incubation, 10 µL of MTT reagent (5 mg/mL) were added to each well and the plates were incubated at 37 °C for 2h. The plates were then removed from the incubator and the cell media was carefully aspirated off, as not to disturb the newly formed formazan crystals. DMSO (100  $\mu$ L) was added to each well and the plates were rocked for 20 min. Absorbance data were recorded at 570 nm using a plate reader.

**3D** Cell Culture. MDA-MB-231 cells were grown and maintained in phenol red-free DMEM supplemented with 10% FBS, 10mM HEPES, and 100 U/ml penicillin-streptomycin, pH 7.4. For experimental conditions, the media was altered to additionally contain 25mM PIPES, and acidified to pH 6.8. During all conditions, cells were grown in a 37 °C humidified incubator ventilated with 5% CO<sub>2</sub>.

**DQ** Collagen-IV 3D Live Cell Proteolysis Assay. Cleavage of DQ-collagen IV substrate (Life Technologies, Carlsbad, CA, USA) by live MDA-MB-231 cells was assayed in real time and quantified based on published protocols<sup>66-68</sup> with some modifications. Briefly, single cell suspensions of tumor cells were plated on top of coverslips coated with Cultrex<sup>TM</sup> (Trevigen, Gaithersburg, MD, USA) containing DQ-collagen IV (1:40) and overlayed with 2% Cultrex<sup>TM</sup>. Cells were treated with **4**, **5**, **6**, **7**, or vehicle (0.2% DMSO) 24 and 72 h after seeding. With treatment, cells were incubated under dark and light for 20 min at room temperature, incubated 60 min at 37 °C, exposed to dark or light conditions again for 25 min at room temperature, then placed back in the incubator. The overlay was replaced with treatment at 72 h. At 96 h, proteolysis of DQ-collagen IV was imaged by capturing z-stacks through the depth of structures using a Zeiss LSM 780 confocal microscope with a 40x water immersion objective. Intensity of green fluorescence/tumor spheroid was quantified in each 3D reconstructed spheroid using Volocity Software (Perkin Elmer, Waltham, MA, USA).

**3D** Cytotoxicity Assay. The cytotoxicity of the compounds was assayed on live MDA-MB-231 cells using Molecular Probes<sup>TM</sup> Live/Dead Viability/Cytotoxicity Kit (Invitrogen, Carlsbad, CA, USA). Briefly, single cell suspensions of tumor cells were plated on top of coverslips coated with Cultrex<sup>TM</sup> and overlayed with 2% Cultrex<sup>TM</sup>. Cells were treated with **4**, **5**, **6**, **7**, or vehicle (0.2% DMSO) at 24 and 72 h after seeding. With treatment, cells were kept under dark (no irradiation) and light (250 W, 395–750 nm) conditions for 20 min at room temperature, incubated 60 min at 37 °C, exposed to dark or light conditions again for 25 min at room temperature, then placed back in the incubator. The Cultrex overlay was replaced and treatments replenished at 72 h. At 96 h, coverslips were stained with 2  $\mu$ M Calcein AM and 5  $\mu$ M Ethidium homodimer-1 (Live/Dead Viability/Cytotoxicity Kit) for 30 min at room temperature, then rinsed and immediately imaged

by capturing z-stacks through the depth of structures using a Zeiss LSM 780 confocal microscope with a 10x water immersion objective. The live cells, stained green by the Calcein AM, were recorded using excitation at 488 nm, emission at 507 nm. The dead cells, stained red by the Ethidium homodimer-1, were recorded using excitation at 488 nm, emission at 730 nm. Care was taken so there was no overlap between emission from red and green channels. Sum of channel intensity was quantified using Volocity software, and percentage of live cells to total cells was calculated, indicative of compound toxicity.

**Fluorescent Cathepsin B Imaging**. The ability of **3** to track the localization of CTSB in live MDA-MB-231 cells was examined by confocal microscopy. Briefly, single cell suspensions of tumor cells were plated on top of coverslips coated with Cultrex<sup>TM</sup> and overlayed with 2% Cultrex<sup>TM</sup>. After 72 h of growth, cells were treated with **3** (5–10  $\mu$ M) or vehicle (0.2% DMSO) for 30 min at 37 °C. During the final 3-5 min, 10  $\mu$ M of DRAQ5 DNA fluorescent probe was added (to label the nuclei). Cells were washed with PBS and imaged by capturing z-stacks through the depth of structures using a Zeiss LSM 780 confocal microscope with a 40x water immersion objective (Ex. 458 nm/Em. 610 nm). Detection wavelengths of 561–659 nm were used to determine the localization of CTSB. The intensity of fluorescence/tumor spheroid was quantified in each 3D reconstructed spheroid using Volocity Software.

#### **Results and Discussion**

# **Compound Design**

Dual action conjugates were designed based on known Ru(II) complexes with pyridine as the leaving ligand (Figure 4). Prior studies revealed that variation of bidentate ligands (NN) in

complexes of the general formula  $[Ru(tpy)(NN)(py)]^{2+}$ , where NN was equal to 2,2'-bipyridine (bpy), 6,6'-dimethyl-2,2'-bipyridine (Me2bpy), benzo[*i*]dipyrido[3,2-*a*:2',3'-*c*]phenazine (dppn) or 3,6-dimethylbenzo[*i*]dipyrido[3,2-*a*:2',3'-*c*]phenazine (Me<sub>2</sub>dppn), provided high levels of control over quantum efficiencies of monodentate pyridine photorelease and generation of  ${}^{1}O_{2}$ . <sup>58,59</sup> The complex  $[Ru(tpy)(bpy)(py)]^{2+}$  represents a control that neither photoreleases pyridine nor produces  $^{1}O_{2}$ . The dppn ligand in [Ru(tpy)(dppn)(py)]<sup>2+</sup> produces  $^{1}O_{2}$  with 98% efficiency due to the lowest energy dppn-centered  ${}^{3}\pi\pi^{*}$  excited state, but does not undergo ligand dissociation.<sup>58</sup> In contrast, incorporation of methyl groups that point towards the metal in Me<sub>2</sub>bpy and Me<sub>2</sub>dppn provides the necessary steric bulk to lower the energy of the dissociative <sup>3</sup>MC state, promoting ligand release upon irradiation. Of particular interest was [Ru(tpy)(Me<sub>2</sub>dppn)(py)]<sup>2+</sup>, which is able to both photorelease pyridine and generate  ${}^{1}O_{2}$  in water. We surmised that the dual photoreactivity of  $[Ru(tpy)(Me_2dppn)(py)]^{2+}$  could be especially useful in targeting cancer cells for PDT if methods for cell-specific delivery were developed. In particular, photorelease was postulated to provide an advantage for achieving cellular uptake and favorable subcellular localization of the Ru(II) photosensitizer.



**Figure 4.** Dual active Ru(II) complexes of the general formula  $[Ru(tpy)(NN)(py)]^{2+}$  that show photorelease and <sup>1</sup>O<sub>2</sub> photosensitization.

CTSB was chosen as a target for cell-specific delivery because it is highly upregulated in a broad range of cancers (breast, melanoma, GBM, esophageal, pancreatic, colorectal and prostate), trafficked to the cell surface and secreted by cancer cells and TAMs.<sup>69</sup> CTSB is associated with invasive and metastatic behavior and serves as an essential enzyme for activating various signaling pathways at tumor sites, including activation of matrix metalloproteases (MMPs) and urokinase plasmodium activators that cleave the extracellular matrix,<sup>1,70,71</sup> as well as an adaptive response to chemotherapy.<sup>20</sup> We chose to use compound **2**, a derivative of the potent and selective CTSB inhibitor CA074,<sup>72</sup> as the inhibitor and delivery vector (Figure 3). Derivative **2** (Figure 5) was designed based on NS-134 (Figure 3),<sup>61</sup> a CA074 analog that spans the entire active site cleft of CTSB and has shown promising results as a vector for *in vivo* delivery of liposomal

nanoparticles to tumor and stromal cells.<sup>21</sup> The structure of NS-134 was modified to include Ile residues and a terminal propyl nicotinamide group for Ru(II) binding to afford **2**. In addition, bipyridyl derivative **1** (Figure 5) was prepared to provide access to an emissive tris-chelated Ru(II) complex similar to  $[Ru(bpy)_3]^{2+}$  for subcellular tracking. This compound was needed because none of the derivatives from **2** were expected to be luminescent.

A series of Ru(II) conjugates (4–7) with the general formula [Ru(tpy)(NN)(2)](PF<sub>6</sub>)<sub>2</sub> were designed with bidentate ligands NN = bpy (4), Me<sub>2</sub>bpy (5), dppn (6), and Me<sub>2</sub>ddpn (7), and their molecular structures are depicted in Figure 5. In addition, complex **3** was designed to contain a [Ru(bpy)<sub>3</sub>]<sup>2+</sup> fluorophore to track the subcellular localization of the conjugates, whereas compounds **4**–**7** were designed to independently undergo each of the four possible combinations of photoactivated ligand dissociation and/or <sup>1</sup>O<sub>2</sub> generation as shown in Figure 4. Compound **7**, containing the Me<sub>2</sub>dppn ligand, was the only complex expected to exhibit dual behavior, whereas **4**–**6** would serve as controls for evaluating the role that Ru(II) conjugation, ligand dissociation, and ROS formation had independently in controlling biological behavior and cytotoxicity. With each compound, additional control experiments would be performed in cells without irradiation, which was expected to neither release the Ru(II) fragment nor produce ROS.



Figure 5. Structures of A) epoxysuccinyl inhibitors 1 and 2 and B) Ru(II) epoxysuccinyl conjugates 3–7.

# **Compound Synthesis**

The syntheses of inhibitors **1** and **2** were accomplished starting from commercially available **8** (Scheme 1). DCC-HOBT coupling of Z-*L*-Ile-OH (**8**) with H-Pro-O*t*-Bu (**9**) gave dipeptide **10** in 98% yield. Compound **10** was subjected to hydrogenolysis using Pearlman's

catalyst to remove the Cbz protecting group, which was followed by EDC coupling with known diacid **11**, obtained in four steps from *D*-tartatric acid,<sup>73</sup> to give monoacid **12** in a moderate yield over two steps.



Scheme 1. Synthesis of carboxylic acid 12

Synthesis of the pyridyl and bipyridyl linkers **17-18** began from known dipeptide **13** (Scheme 2).<sup>74</sup> Dipeptide **13** was subjected to KOH saponification followed by EDC coupling with ethyl glycinate giving tripeptide **14** in a combined yield of 69% over two steps. Tripeptide **14** was saponified with KOH and the resultant carboxylic acid was coupled with primary amines  $15^{75}$  or  $16^{76}$  using EDC, giving **17** and **18** in 52% and 54% yields over two steps, respectively. Compounds **17** and **18** were subjected to Boc deprotection using 1:1 mixture of TFA: DCM to form TFA salts, which were combined with a *p*-nitrophenol ester derived from **12**, giving **19** and **20** in moderate yields (Scheme 3).



Scheme 2. Synthesis of linkers 17 and 18.



(R = H) (37 %, 3 steps)

Scheme 3. Synthesis of pyridine-based CTSB inhibitors 19 and 20

The syntheses of  $[Ru(bpy)_2(1)](O_2CCF_3)_2$  (**3**) and  $[Ru(tpy)(NN)(1)](PF_6)_2$  (**4–7**) are shown in Schemes 4A and 4B, respectively. Analog **19** was treated with *cis*- $[Ru(bpy)_2Cl_2]$  with heating at 80 °C in ethanol giving  $[Ru(bpy)_2(1)]Cl_2$  as an intermediate which was then subjected to *t*-butyl ester deprotection using TFA:DCM (1:1) to obtain compound **3** as a mixture of  $\Delta$  and  $\Lambda$ stereoisomers in 32% yield over the two steps. Counteranion exchange of chloride for trifluoroacetate occurred during this step through removal of volatile HCl gas. In order to synthesize ruthenium conjugate complexes **4–7**, the respective  $[Ru(tpy)(NN)Cl]Cl^{77,78}$  complexes were converted into [Ru(tpy)(NN)OTf]OTf complexes by overnight heating in ethanol at 80 °C with AgOTf, followed by filtration over celite to remove AgCl formed in the reaction. Treating respective [Ru(tpy)(NN)OTf]OTf complexes with 1.1 equiv of inhibitor **2** in EtOH at 80 °C for 6 h, followed by concentration resulted in inhibitor metalation, which upon chromatographic purification over neutral alumina and subsequent *t*-butyl ester deprotection using 1:1 TFA:DCM gave final complexes [Ru(tpy)(NN)(**2**)](PF<sub>6</sub>)<sub>2</sub> **4**–**7** 25% to 34% yield over three steps. Compounds **3**–**7** were characterized by using UV-Vis absorption, <sup>1</sup>H NMR, and IR spectroscopies, mass spectrometry and elemental analysis.

Α 1) Rpy(19) EtOH, reflux, 5 h  $\Delta, \Lambda$ -3 cis-[Ru(bpy)<sub>2</sub>Cl<sub>2</sub>] 2) TFA/DCM 0 °C to RT, 4 h В 1) AgOTf, EtOH reflux, ON 4-6 [Ru(tpy)(NN)CI]CI 2) Rpy(**20**) EtOH, reflux, 5 h NN = bpy, Me<sub>2</sub>bpy  $NH_4PF_6$ dppn or Me<sub>2</sub>dppn 3) TFA/DCM 0 °C to RT, 4 h

Scheme 4. Synthesis of A)  $\Delta$ ,  $\Lambda$ -[Ru(bpy)<sub>2</sub>(1)](O<sub>2</sub>CCF<sub>3</sub>)<sub>2</sub> (3) (A) and B) [Ru(tpy)(NN)(2)](PF<sub>6</sub>)<sub>2</sub> complexes, where NN = bpy (4), Me<sub>2</sub>bpy (5), dppn (6) and Me<sub>2</sub>dppn (7), see Figure 4 for bidentate ligand (NN) structures.

#### **Structural Characterization Data**

<sup>1</sup>H NMR spectroscopic analysis of Ru(II) conjugates **4–7** shows resonances corresponding to the Ru(II) complex and epoxysuccinyl inhibitor fragments of the conjugates. The <sup>1</sup>H NMR

consistent

spectrum of compound 7 in methanol-d4 shows an additional peak in the aromatic region at 7.30 ppm which corresponds to the 5-pyridyl C-H of the monodentate nicotinamide donor. The doublet at 7.93 ppm is assigned to the 4-pyridyl C-H based on its coupling constant. A resonance corresponding to the 2-pyridyl CH proton is merged with other peaks in the multiplet at ~8.25 ppm. Two singlets at 2.38 and 1.82 ppm, which integrate to three protons each, belong to the two methyl groups on the Me<sub>2</sub>dppn ligand that are in unique chemical environments, one above and one below the plane formed by the Ru(tpy) unit. Similar data were observed for compounds 3-6.

Electrospray mass spectra of conjugates 3 and 4 show major peaks at 610.7, along with expected isotopic distributions, which are consistent with  $[Ru(bpy)_2(1)]^{2+}$  and  $[Ru(tpy)(bpy)(2)]^{2+}$ dications derived from 2 and 3, respectively (Figures S41–S44). Similarly, spectra for complexes 5, 6 and 7 show major peaks at m/z values of 624.7, 698.7 and 712.7 respectively, which are  $[Ru(tpy)(Me_2bpy)(2)]^{2+}$ ,  $[Ru(tpy)(dppn)(2)]^{2+}$ with dications and  $[Ru(tpy)(Me_2dppn)(2)]^{2+}$ (Figures S45–S50).

Complexes 4-7 were evaluated for stability in DMSO at 25 °C and phenol red-free Dulbecco's modified Eagle's cell growth medium (DMEM) at 37 °C over the course of 24 h by electronic absorption spectroscopy (Figures S58-67). With the exception of 5, which showed spectral changes consistent with partial release of 2 at 37  $^{\circ}$ C in DMEM over the course of 24 h, all complexes were exceptionally stable in the dark, with no observable spectral changes during this time.

#### **Electronic Absorption Spectroscopy and Photochemistry**

The electronic absorption spectra for ruthenium complexes 3–7 are shown in Figure 6. Complexes 3-7 exhibit maxima between ~ 450 and 490 nm in methanol, consistent with metal-to-

ligand charge transfer (MLCT) bands. The maximum of **4** is observed at 461 nm ( $\varepsilon = 8800 \text{ M}^{-1} \text{ cm}^{-1}$ ) and a shoulder is visible at ~415 nm. The <sup>1</sup>MLCT maximum of **5**, at 469 nm, is bathochromically shifted relative to **4**, consistent with the corresponding pyridine analogs previously reported and attributed to the distorted octahedral geometry of the former, thus destabilizing the HOMO.<sup>58</sup> Complex **6** exhibits a <sup>1</sup>MLCT maximum at 471 nm ( $\varepsilon = 13800 \text{ M}^{-1}\text{ cm}^{-1}$ ) and two peaks at 385 and 405 nm associated with the known dppn-centered <sup>1</sup> $\pi\pi^*$  transitions.<sup>58</sup> In a manner similar to the red-shift between complexes **4** and **5**, the <sup>1</sup>MLCT maximum of **7** is observed at 482 nm. This complex also possesses Me<sub>2</sub>dppn-centered bands at 380 and 402 nm as previously reported for [Ru(tpy)(Me<sub>2</sub>dppn)(py)]<sup>2+.58</sup>



Figure 6. Electronic absorption spectra of 3 (brown), 4 (blue), 5 (green), 6 (black) and 7 (red) in MeOH.

The irradiation of complexes **5** and **7** with visible light ( $\lambda_{irr} \ge 475 \text{ nm}$ ) in H<sub>2</sub>O results in the release of **2**, with the concomitant coordination of solvent to generate the corresponding aqua complex (Figure 7). Irradiation of **5** in CH<sub>3</sub>CN results in a blue shift of the <sup>1</sup>MLCT transition from 469 nm to 453 nm (Figure S51A), whereas a red shift from 469 nm to 481 nm is observed in H<sub>2</sub>O, consistent with the formation of the corresponding [Ru(tpy)(Me<sub>2</sub>bpy)(L)]<sup>2+</sup> (L = CH<sub>3</sub>CN, H<sub>2</sub>O)

complex as previously reported for related complexes.<sup>65</sup> Similarly, the irradiation of N<sub>2</sub> purged solutions of 7 results in a blue shift of the <sup>1</sup>MLCT maximum from 482 nm to 464 nm in CH<sub>3</sub>CN and a modest red shift from 482 nm to 487 nm in H<sub>2</sub>O. The quantum yields of photoinduced ligand exchange with  $\lambda_{irr} = 500$  nm,  $\Phi_{500}$ , were determined to be 0.15(1) and 0.11(1) for 5 and 7, respectively, in CH<sub>3</sub>CN under N<sub>2</sub> (Table 1). In H<sub>2</sub>O,  $\Phi_{500}$  values for 5 and 7 were measured to be 0.092(4) and 0.0070(6), respectively. The lower quantum yields observed in H<sub>2</sub>O are attributed to the lower solubility of 2 in this solvent, reducing the escape of 2 from the solvent cage in  $H_2O$ relative to CH<sub>3</sub>CN, as previously observed for related systems.<sup>79</sup> To confirm the release of **2** from 5 and 7, changes to the <sup>1</sup>H NMR spectrum as a function of irradiation time were recorded in  $D_2O$  $(\lambda_{irr} \ge 475 \text{ nm})$ , which resulted in new resonances corresponding to free 2 with the concomitant  $[Ru(tpy)(Me_2bpy)(D_2O)]^{2+}$ of corresponding to appearance resonances and  $[Ru(tpv)(Me_2dppn)(D_2O)]^{2+}$  (Figure S52–S57).<sup>80</sup>



**Figure 7.** Changes to the electronic absorption spectra of **5** (A) and N<sub>2</sub> purged **7** (B) in H<sub>2</sub>O as a function of irradiation time ( $\lambda_{irr} \ge 475$  nm) for 0 – 4 min and 0 – 11 min, respectively.

The presence of the dppn and Me2dppn ligands in **6** and **7**, respectively, is known to afford a long-lived dppn-centered  ${}^{3}\pi\pi^{*}$  excited state in this class of complexes that is able to undergo energy transfer with ground state  ${}^{3}O_{2}$  in solution.<sup>58,59</sup> Therefore, in addition to the release of **2**, complex **7** sensitizes  ${}^{1}O_{2}$  with  $\Phi_{\Delta}= 0.58(3)$  with  $\lambda_{irr} = 460$  nm. Complex **6**, for which ligand photodissociation is not observed ( $\Phi_{LE} < 10^{-4}$ ), sensitizes  ${}^{1}O_{2}$  more efficiently, resulting in  $\Phi_{\Delta} =$ 0.83(3) with  $\lambda_{irr} = 460$  nm. The lower yield of  ${}^{1}O_{2}$  sensitization in **7** is attributed to competitive population of  ${}^{3}MC$  and  ${}^{3}\pi\pi^{*}$  states, as previously discussed in detail for the corresponding pyridine parent complexes,  $[Ru(tpy)(dppn)(py)]^{2+}$  and  $[Ru(tpy)(diMedppn)(py)]^{2+}$ .<sup>58,59</sup> Complex **3** is moderately emissive at room temperature with a maximum at 675 nm, luminescence lifetime,  $\tau_{em}$ , of 69.1 ns ( $\lambda_{exc} = 444.4$  nm), and emission quantum yield,  $\Phi_{em}$ , of 0.0029(1) in H<sub>2</sub>O ( $\lambda_{exc} = 460$  nm). In contrast to [Ru(bpy)<sub>3</sub>]<sup>2+</sup>, the short excited state lifetime of **3** precludes its bimolecular sensitization of <sup>1</sup>O<sub>2</sub>, which allows for the use of **3** as a nontoxic fluorescent probe.

**Table 1.** Quantum yields for ligand exchange ( $\Phi_{500}$ ) and  ${}^{1}O_{2}$  production singlet oxygen ( $\Phi_{\Delta}$ ) by Ru(II) compounds **3–7**.

Compound	$\Phi_{500}{}^{\mathrm{a}}$	$\Phi_{500}{}^{\mathrm{b}}$	$\Phi_{\Delta^c}$	$\Phi_{ m em}{}^{ m c}$
3				0.0031(1)
4	<10 <sup>-4</sup>	<10 <sup>-4</sup>		
5	0.092(1)	0.15(1)		
6	<10 <sup>-4</sup>	$< 10^{-4}$	0.83(3)	
7	0.0070(6)	0.11(1)	0.58(3)	

<sup>a</sup> In 2% CH<sub>3</sub>OH/H<sub>2</sub>O with  $\lambda_{irr}$  = 500 nm. <sup>b</sup> In CH<sub>3</sub>CN with  $\lambda_{irr}$  = 500 nm. <sup>c</sup> In CH<sub>3</sub>OH.

#### **Distribution Coefficients**

The cellular uptake and localization of ruthenium complexes rely significantly on their lipophilicity,<sup>81</sup> exhibiting enhanced cellular uptake with an increase in the lipophilic character of the compounds. Also, the lipophilicity of compounds containing acidic or basic functional groups varies considerably with pH. The distribution measured between octanol and aqueous buffer at a particular pH is termed as the distribution coefficient.<sup>82</sup> The distribution coefficient between octanol and buffer at pH = 7.00 preeminently mimics physiological conditions. Therefore, we evaluated distribution coefficient (log $D_{7.00}$ ) for complexes **3**–**7**. As shown in Table 2, the log $D_{7.00}$ 

values for 6 and 7 were measured to be -0.11 and -0.06, respectively, and are more lipophilic than 3–5, as expected from the presence of the hydrophobic dppn and  $Me_2dppn$  ligands in the former. Contrasting data for  $[Ru(tpy)(Me_2dppn)(py)](PF_6)_2$ , with log  $D_{7,00} = 0.26$ , to conjugate 7 reveals that the CTSB inhibitor plays a significant role in reducing the overall hydrophobicity, driving the log  $D_{7.0}$  value for 7 to -0.06. The lower log  $D_{7.00}$  value of 7 relative to the py model complex  $[Ru(tpy)(Me_2dppn)(py)]^{2+}$  is expected to favor the targeting of extracellular CTSB. In addition, these data underscore the importance of controlling the overall charge of the complex; dication  $[Ru(tpy)(Me_2dppn)(py)]^{2+}$  is one order of magnitude less lipophilic than monocation [Ru(tpy)(Me<sub>2</sub>dppn)(Cl)]<sup>+</sup> (Table 3), which is consistent with literature data.<sup>83</sup> Importantly, we do not yet understand what form the photosensitizer takes after release from 7, i.e. what ligand traps the vacant coordination site on Ru(II) after photolysis. Given the high extracellular chloride concentration found in vitro and in vivo (100-140 mM), monocationic chloride derivatives such as [Ru(tpy)(Me<sub>2</sub>dppn)(Cl)]<sup>+</sup> could be formed in the extracellular space that are taken up by cells. Indeed, treating  $[Ru(tpy)(bpy)(H_2O)]^{2+}$  with 110 mM NaCl in H<sub>2</sub>O results in formation of [Ru(tpy)(bpy)(Cl)] + within ~1 h at 37.5 °C (data not shown) and recent data confirm that media.<sup>84</sup> relatively slow to aquate in aqueous Treating  $[Ru(tpy)(bpy)(Cl)]^+$  is [Ru(tpv)(Me<sub>2</sub>bpv)(H<sub>2</sub>O)]<sup>2+</sup> with 110 mM NaCl in H<sub>2</sub>O at 37.5 °C also results in conversion to the respective monocationic chloride complex, but with lower efficiency; the steric bulk afforded by the methyl groups on the bidentate ligand is most likely responsible for the observed shift in the equilibrium. Similarly, addition of  $[Ru(tpy)(Me_2dppn)(H_2O)_2]^{2+}$  to an aqueous solution containing 110 mM NaCl results in the formation of [Ru(tpy)(Me<sub>2</sub>dppn)(Cl]<sup>+</sup>, albeit in low yield (~10%). Taken together these data strongly suggest that our Ru(II) photosensitizers that undergo chloride

exchange may accumulate in the mitochondria, which is favored for cations with log *P* values  $1-5^{85}$  and has already been shown for similar Ru(II)-based photosensitizers.<sup>86</sup>

 Table 2. Distribution coefficients of complexes 3–7 between octanol and 10 mM sodium

 phosphate saline buffer (PBS) measured using "Shake-Flask" method.<sup>82</sup>

Compound	$\log D_{7.00}^{\mathrm{a}}$
3	-1.37 (0.16)
4	-1.69 (0.01)
5	-1.12 (0.19)
6	-0.11 (0.05)
7	-0.06 (0.02)
[Ru(tpy)(Me <sub>2</sub> dppn)(py)](PF <sub>6</sub> ) <sub>2</sub>	0.26 (0.04)
[Ru(tpy)(Me <sub>2</sub> dppn)Cl]Cl	1.27 (0.06)

 $^aConcentrations$  of complexes ranged between 55 and 75  $\mu M$ 

## **CTSB** Inhibition

Compounds 1–7 were examined for inhibition of purified CTSB. Inhibition was determined in the dark by progress curve analysis using hydrolysis of the fluorogenic substrate Z-Arg-Arg-AMC (Table 3). Data were fit to a two-step model for irreversible inhibition, which provides the equilibrium constant for the reversible association between inhibitor and CTSB (K<sub>i</sub>) and the rate constant for irreversible inactivation (k<sub>inact</sub>), including covalent bond formation via epoxide opening. The quotient k<sub>inact</sub>/K<sub>i</sub> represents the second-order rate constant for enzyme inactivation. Inhibitors 1–7 all potently and irreversibly inhibit CTSB at extremely low concentrations (0.25– 10 nM), with k<sub>inact</sub>/K<sub>i</sub> values ranging from 4.3–6.3 × 10<sup>6</sup> M<sup>-1</sup> s<sup>-1</sup>, which are amongst the most potent irreversible inhibitors of CTSB known to date.<sup>87-91</sup> Taken together, these inhibition data confirm that a broad range of Ru(II) complexes are tolerated by CTSB.

Compound	$K_{i}(\mu M)$ $k_{inact}(s^{-1})$		$\mathbf{k}_{\mathbf{inact}}/\mathbf{K}_{\mathbf{i}}$ (M <sup>-1</sup> s <sup>-1</sup> )
	$\times 10^{-3}$	$\times 10^{-3}$	$\times 10^3$
1	$6.8 \pm 0.4$	34.5 ± 2.1	$5100 \pm 600$
2	8.5 ± 1.3	44.6 ± 9.7	$5300 \pm 1300$
3	$4.3 \pm 0.8$	$23.7\pm3.8$	$5600\pm400$
4	$7.6 \pm 0.7$	38.0 ± 6.1	$5000 \pm 1300$
5	$8.8 \pm 1.1$	37.0 ± 5.6	$4300\pm800$
6	$7.4 \pm 1.2$	$40.6\pm12$	$5500 \pm 1400$
7	$8.5 \pm 1.4$	$51.0 \pm 11$	$6300 \pm 2100$

**Table 3.** Kinetic and thermodynamic parameters for inhibition of CTSB.<sup>a</sup>

<sup>a</sup>Conditions: The CTSB stock was diluted to 16 nM (4 nM final concentration) in buffer solution (400 mM sodium acetate, 4 mM EDTA, pH 5.5) containing 8 mM DTT. Inhibitors were prepared as <1% DMSO stock solutions in assay buffer (400 mM sodium acetate, 4 mM EDTA, 0.01% Triton-X 100, pH 5.5) to achieve final concentrations ranging from 0.25-10 nM. The substrate Z-Arg-Arg-AMC in assay buffer (200  $\mu$ M, 50  $\mu$ L) was diluted to achieve a final concentration of 100  $\mu$ M.

## **Cell Studies**

After confirming that **4**–**7** potently inhibit purified CTSB, compounds, these complexes were evaluated against MDA-MB-231 TNBC cells in 2D culture. Cells were treated with **4**–**7** (1–10  $\mu$ M), incubated for 4 h then irradiated (Light,  $\lambda_{irr} > 395$  nm) using a two-stage irradiation sequence to allow for Ru(II) photodissociation (Stage 1, t = 0–20 min), a 60 min delay to allow uptake of

the photosensitizer, then irradiation for ROS generation (Stage 2, t = 80-105 min). Cells under dark conditions were treated in the same manner without irradiation. After 72 h, viability was determined using the MTT assay. Results indicated that no growth inhibitory effects were observed for compounds **4–7** at concentrations of 1 and 5  $\mu$ M (data not shown). At concentrations of 10  $\mu$ M, **7** was the only complex that reduced viability outside the range of error relative to the control cells treated with vehicle only (Figure 8). Furthermore, the Me<sub>2</sub>ddpn derivative **7** showed significantly enhanced cell killing relative to that observed in the dark, reducing viability to roughly 60% of the control level under light conditions vs. ~90% in the dark. In order to gain insight into the selectivity of **7** for cancer vs. non-cancer cell lines, **7** was evaluated against the normal breast epithelial cell line MCF-10A under the same conditions as those used with the TNBC MDA-MB-231 line. Viability was determined after 72 h using the MTT assay and results showed that **7** did not reduce viability in the normal breast epithelial line under light or dark conditions (Figure 8) below the level of control, confirming that selectivity between cancer vs. non-cancer cell lines can be obtained.





**Figure 8.** Cell viability assay results for compounds **4–7** (10µM) against MDA-MB-231TNBC cells and compound **7** (10 µM) against MCF-10A breast epithelial cells. Cells were treated with 1% DMSO (Control), or indicated compound and placed under dark conditions (Dark), or irradiated with light (Light,  $\lambda_{irr} > 395$  nm, t = 0–20 then 80–105 min). Cell viability was determined by the MTT assay after 72 h and is reported relative to control with only vehicle added. Error bars represent the standard error of mean of triplicate wells, and data are representative of three independent experiments.

Next, compounds **4–7** were evaluated in a 3D pathomimetic model of TNBC. As opposed to assays using purified enzymes or 2D monolayer culture, where *in vivo* characteristics are not recapitulated, 3D culture experiments take into consideration interactions of cells with the extracellular matrix (ECM), cell polarity and cell-to-cell contacts, thus providing a more accurate

Page 31 of 48

context in which to evaluate compound activity and protease inhibition.<sup>92,93</sup> As a result, efficacy studies from 3D culture experiments correlate closer with *in vivo* results than 2D culture experiments.<sup>94</sup> In addition to employing 3D reconstituted basement membrane overlay cultures with the MDA-MB-231 TNBC cells, we performed all experiments at an acidified extracellular medium at a pH of 6.8. Extracellular acidification is a critical property of invasive and metastatic tumors. At later stages, as cancer cells become more aggressive and shift their metabolism from oxidative phosphorylation (OXPHOS) to aerobic glycolysis they produce more lactic acid, which in turn is secreted into the extracellular space and favors the proteolytic activity of cysteine proteases.<sup>12</sup> This process is essential for cancer cells to invade outside the tumor margins. Importantly, previous studies confirmed that 3D culturing of cells at pH 6.8 increases the translocation of CTSB from lysosomes to the cell surface and extracellular milieu as compared with pH 7.4.<sup>12</sup> CTSB was a major contributor to the enhanced proteolytic degradation of collagen IV in the pericellular space in these experiments.

The first goal with compounds **4–7** was to measure their ability to inhibit extracellular proteolysis and CTSB in 3D culture. A dye-quenched version of collagen IV (DQ-collagen IV) was used to mimic the ECM found *in vivo*. DQ-collagen IV is labeled with multiple equivalents of fluorescein and is quenched until proteolytically degraded. When the fluorophore-peptide fragments become separated, the dye is no longer quenched, and green fluorescence is observed. Our data confirm that all four compounds (**4–7**) potently inhibit DQ-collagen IV degradation vs. DMSO control (P < 0.001 for **6–7**) under both light and dark conditions. For light conditions, the same irradiation sequence was used as for the 2D experiments ( $\lambda_{irr} > 395$  nm, Stage 1, t = 0–20 min, Stage 2, t = 80–105 min). Data representative of the group are shown for compounds **6** and **7** in Figures 9 and 10. Data for **5** and **6** are shown in Figures S11–S12. In our previously published

examples of Ru(II)-caged inhibitors, high dark to light ratios were achieved because the Ru-bound inhibitors did not interact with the enzyme.<sup>56,65,95-97</sup> This behavior was not expected for **4–7**, since the inhibition is not affected by the coordination to the metal, such that similar levels of inhibition under light and dark conditions were predicted for these complexes. These data prove that the coordination of the inhibitors to the Ru(II) center does not strongly influence inhibition of CTSB in the 3D assay by our compounds, similar to results achieved with purified CTSB described above. Furthermore, the large-scale reduction in extracellular proteolysis observed with **4–7** strongly suggests that CTSB is the major contributor to proteolytic degradation of the ECM at pH 6.8, a key feature of invasive cancer cells, which agrees well with previously reported data.<sup>12</sup>





**Figure 9.** Representative images of DQ collagen IV proteolysis by MDA-MB-231 cells in the absence or presence of complexes **7** and **6**. Cells were treated with DMSO (Control, **A**, **D**), 5  $\mu$ M complex **7** (**B**, **E**), or 5  $\mu$ M complex **6** (**C**, **F**) and treated under dark conditions (Dark, **A-C**), or irradiated with light (Light,  $\lambda_{irr} > 395$  nm, t = 0–20 then 80–105 min, **D-F**). Cells were imaged and the z-stack was reconstructed to show DQ collagen IV degradation (green); 1 grid unit = 21.34  $\mu$ m.



**Figure 10.** Quantification of DQIV proteolysis by MDA-MB-231 cells. Cells were treated with DMSO (Control) or 5  $\mu$ M complex **6**, or 5  $\mu$ M complex **7** and placed under dark conditions (Dark) or irradiated with light (Light,  $\lambda_{irr} > 395$  nm, t = 0–20 then 80–105 min). DQ-collagen IV degradation was quantified using Volocity software. Data are shown as fluorescence intensity upon treatment relative to control (no treatment) conditions. Results shown depict representative experiment with four individual spheroid reconstructions.

Following the confirmation that our compounds inhibit proteolysis, the cytotoxicity for 4–7 was measured in the 3D pathomimetic assay. Cells were seeded, then treated with 4–7 (5  $\mu$ M) at 24 and 72 h. With treatment, cells were incubated under dark (Dark) and light (Light,  $\lambda_{irr} > 395$  nm, t = 0–20 then 80–105 min) conditions. After 96 h viability was assessed using Calcein AM, which labels live cells (green) and ethidium homodimer-1 that labels dead cells (red) upon DNA intercalation. Strikingly, our data show that only compound 7, which combines photodissociation and  ${}^{1}O_{2}$  generation into one chemical entity, is able to reduce viability to <10 % relative to vehicle control under light conditions (P < 0.001); in the dark, 7 is not toxic (Figure 7B-D). Compounds

**4**–**6** all show high levels of cell viability under dark and light conditions that was within error of the 100% viability with vehicle control; representative imaging data for compounds **6** and **7** are shown in Figure 11; imaging data for compounds **4** and **5** are shown in Figure S10 and the quantification of cell death for compounds **4**–**7** are shown in Figure 12. Importantly, **7** under light conditions was significantly more toxic in the 3D experiment (Figure 12) than under 2D culture (Figure 8), which may be attributed to the greater translocation of the CTSB to the cell surface in 3D culture vs. 2D. Taken together, these data prove that photoactivated ligand release and  ${}^{1}O_{2}$  generation are highly important in achieving efficient cell death. Contrasting **6** and **7**, which both generate ROS, strongly suggests that release of the lipophilic Ru(II) photosensitizer to achieve favorable subcellular localization is a critical factor for achieving potent cell death.



**Figure 11.** Representative cytotoxicity images of MDA-MB-231 cells. Cells were treated at 24 and 72 h with DMSO (Control, left; **A**, **D**), 5  $\mu$ M complex 7 (middle; **B**, **E**), or 5  $\mu$ M complex 6 (right; **C**,**F**) and placed under dark conditions (Dark, **A**-**C**), or irradiated with light (Light,  $\lambda_{irr} >$  395 nm, t = 0–20 then 80–105 min, **D**-**F**). After 96 h, cells were stained with 2  $\mu$ M Calcein AM and 5  $\mu$ M ethidium homodimer-1 for 30 min and imaged. Green fluorescence indicates live cells and red fluorescence indicates dead cells. Cell morphology is shown by DIC images (differential interference contrast) **G**) For negative control (100% dead cells) cells were permeablized with 0.2% Triton-X in PBS for 30 minutes prior to staining; bar; 100  $\mu$ m.



**Figure 12.** Quantification of viability assay results for MDA-MB-231 cells in the absence or presence of **7** (A), **6** (B), **5** (C) and **4** (D). Cells were treated with DMSO (Control), or 5  $\mu$ M of indicated compound at 24 and 72 h and viability was determined at 96 h using 5  $\mu$ M Calcein AM and 5  $\mu$ M ethidium homodimer-1 as described in Figure 11. Cells were imaged by capturing z-stacks through the depth of structures using a Zeiss LSM 780 confocal microscope. Calcein AM fluorescence intensity indicating live cells was quantified using Volocity Software (Perkin Elmer, Waltham, MA, USA). Data were analyzed using GraphPad Prizm software and are shown as percent of live/total cells under dark (black) or light (green) conditions.

In order to gain insight into the subcellular localization of the Ru(II) conjugates, a live cell 3D imaging assay was carried out with the fluorogenic  $[Ru(bpy)_3]^{2+}$  derivative **3**. Cells were seeded and treated after 72 h with **3** (5–10 µM) or vehicle control, incubated for 30 min at 37°C, then the DRAQ5 DNA fluorescent probe was added to label the nuclei (Figure 13). These imaging experiments show that pericellular staining of CTSB occurs along the invasive edge of the cell

groups, which is consistent with the known association of CTSB with the cell membrane of MDA-MB-231 cells. Because cells were washed after staining, secreted CTSB stained with **3** was likely washed away, similar to previous reports with ABPs.<sup>12</sup>



**Figure 13.** Evaluation of Cathepsin B labeling in MDA-MB-231 spheroids. Cells were treated with DMSO (**A**,**D**), 5  $\mu$ M complex **3** (**B**, **E**), 10  $\mu$ M complex **3** (**C**, **F**). Cells were imaged and the z-stack was reconstructed to visualize Complex **3**-labeled CTSB (red); 1 grid unit = 21.34  $\mu$ m.

This manuscript describes the combination of a photochemotherapy (PCT) agent and a PDT  ${}^{1}O_{2}$  photosensitizer into a single molecule, where light triggers ligand dissociation and generation of  ${}^{1}O_{2}$ . An important feature of Ru(II) complexes is that they absorb strongly in the

visible range into metal-to-ligand charge transfer (MLCT) states that undergo intersystem crossing with 100% yield to populate the corresponding <sup>3</sup>MLCT state.<sup>98</sup> Coordination of a ligand that possesses a ligand-centered  ${}^{3}\pi\pi^{*}$  state that falls below the <sup>3</sup>MLCT results in excited states with long lifetimes, 20–50 µs, that efficiently produce  ${}^{1}O_{2}$ .<sup>59</sup> In addition, in complexes with a coordination environment distorted from ideal octahedral geometry, the metal-centered state(s) of antibonding character are lower in energy and can be populated from the <sup>3</sup>MLCT state, resulting in ligand dissociation; this is the major mechanism exploited here for photosensitizer release. We have already shown that it is possible to both generate  ${}^{1}O_{2}$  and release a ligand upon irradiation.<sup>58</sup> The presence of the Ru(II) center provides several advantages: low-energy absorption by the MLCT state not possible with the ligand alone, overall positive charge for solubility, cell penetration, and subcellular localization, and the ability of these systems to populate two excited states with good yield for dual activity.

Many methods for drug delivery take advantage of the differences between cancer and normal cell surfaces. However, our method uses a delivery vector to achieve irreversible inactivation of a cancer target. Importantly, current delivery strategies for PDT drugs do not irreversibly inhibit crucial activity in cancer.<sup>99-104</sup> Instead these approaches rely on ligand-receptor interactions on the surface, which on their own show little anticancer activity. A notable exception is photodynamic quenched ABPs based on cathepsin inhibitors.<sup>105</sup> While these probes do inactivate cysteine cathepsins, accumulate in tumors *in vivo* and contain an innovative method for photosensitizer activation, the PDT agent remains covalently bound and is not released from the enzyme-inhibitor conjugate after inactivation which limits their efficacy. These probes accumulate in lysosomes, which is typically less effective for PDT than agents that can reach mitochondria or other organelles.<sup>29,106</sup> In contrast, our method of photosensitizer release allows for a traceless and

clean break of the PDT agent from the delivery vector, presumably from the CTSB-inhibitor conjugate. We expect this will provide a distinct advantage over other deliverable PDT agents that either stay ligated to the delivery vector, or rely on enzymatic reactions to cleave the linker between the photosensitizer and the vector because the vector and/or linker can alter membrane permeability and subcellular localization of the PDT agent.<sup>107,108</sup> Further experiments will be needed to determine the subcellular localization of our Ru(II) photosensitizers before and after irradiation.

Our delivery strategy is strongly supported by recent developments in activity-based probes (ABPs) and fluorescence-guided surgery, which demonstrate that overexpression of cysteine cathepsins can be used to identify cancer and tumor-associated cells in vivo.<sup>6-12,109</sup>Importantly, researchers have taken advantage of high extracellular concentrations of proteases at tumor sites to effect the proteolytic release of PDT agents and other drugs.<sup>110-114</sup> While the strategy does provide an advantage in amplification, where multiple equivalents of drug can be released through the catalytic action of tumor-associated proteases, it does nothing to inactivate proteases that are associated with invasiveness and metastatic behavior. Our strategy is a true combination therapy that achieves stoichiometric inactivation of CTSB target with release of a catalyst that generates <sup>1</sup>O<sub>2</sub> to induce cell death. Given that high levels of synergy have already been reported in combining PDT and cysteine cathepsin inhibition in vivo for the treatment of breast cancer,<sup>115</sup> our conjugates or derivatives thereof are promising leads for the development of novel breast cancer therapeutics. Although our method will be more effective for early stage and localized disease than for latestage metastatic cancer, we propose it will extend PDT to breast cancer, a cancer type for which there are not clinically approved protocols in place.<sup>116,117</sup> In particular, new approaches for treating TNBC are needed, because TNBC is especially hard to eradicate with follow-up chemotherapy

including tamoxifen or trastuzumab that work for ER or HER2 positive types.<sup>118</sup> We plan to explore topical application of our dual-action conjugates after surgical resection with subsequent irradiation inside the tumor cavity, which would help to avoid issues of hypoxia associated with larger tumors and light penetration through the skin, where melanin is the principle component that absorbs light >600 nm.

#### Conclusion

In conclusion, we report the synthesis and biological evaluation of dual action Ru(II) photosensitizer conjugates. Epoxysuccinyl-based inhibitors of CTSB conjugated to five Ru(II) complexes (3–7) were synthesized and fully characterized. Compounds 3–7 inactivate purified CTSB in the low nM range and halt degradation of the extracellular matrix in a 3D pathomimetic model of TNBC. Collectively our data confirm that photoactivated ligand release of the photosensitizer (PCT) and generation of  ${}^{1}O_{2}$  (PDT) are crucial for achieving potent cell death. Further development of compounds that combine protease inactivation as a delivery method with photorelease and photosensitization, including Ru(II) complexes that are released and activated in the red visible and near-IR ranges, are ongoing in our laboratories.

# Acknowledgements

We gratefully acknowledge the National Institutes of Health (EB 016072), National Science Foundation (CHE 1800395) and Wayne State University (Rumble Fellowship to K.A.) for support of this research.

## **Supporting Information**

The Supporting Information is available free of charge on the internet at www.acs.org:

Experimental procedure for synthesis of 1–20 with spectral characterization data; progress curves for CTSB inactivation; Live/Dead Cell and DQ-collagen proteolysis imaging data; photochemical data including time-resolved electronic absorbance and <sup>1</sup>H NMR spectra for **5**, **7** after irradiation; time resolved electronic absorption spectra for **4–7** in DMSO (25 °C) and DMEM cell growth media (37 °C)

Author Information

**Corresponding Authors** 

\*Email:jkodanko@chem.wayne.edu, turro.1@osu.edu, ipodgors@med.wayne.edu

# References

(1) Mohamed, M. M.; Sloane, B. F. *Nat. Rev. Cancer* **2006**, *6*, 764-775.

(2) Joyce, J. A.; Hanahan, D. *Cell Cycle* **2004**, *3*, 1516-1519.

(3) Kramer, L.; Turk, D.; Turk, B. Trends Pharm. Sci. 2017, 38, 873-898.

(4) Yim, J. J.; Tholen, M.; Klaassen, A.; Sorger, J.; Bogyo, M. *Mol. Pharmaceutics* **2018**, *15*, 750-758.

(5) Sensarn, S.; Zavaleta, C. L.; Segal, E.; Rogalla, S.; Lee, W.; Gambhir, S. S.; Bogyo, M.; Contag, C. H. *Mol. Imaging Biol.* **2016**, *18*, 820-829.

(6) Withana, N.; Garland, M.; Verdoes, M.; Ofori, L.; Segal, E.; Bogyo, M. Labeling of active proteases in fresh-frozen tissues by topical application of quenched activity-based probes, *Nat. Protoc.* **2016**, *11*, 184-91.

(7) Segal, E.; Prestwood, T. R.; van der Linden, W. A.; Carmi, Y.; Bhattacharya, N.; Withana, N.; Verdoes, M.; Habtezion, A.; Engleman, E. G.; Bogyo, M. *Chem. Biol.* **2015**, *22*, 148-158.

(8) Verdoes, M.; Oresic Bender, K.; Segal, E.; van der Linden, W. A.; Syed, S.; Withana, N. P.; Sanman, L. E.; Bogyo, M. J. Am. Chem. Soc. **2013**, *135*, 14726-14730.

(9) Cutter, J. L.; Cohen, N. T.; Wang, J.; Sloan, A. E.; Cohen, A. R.; Panneerselvam, A.; Schluchter, M.; Blum, G.; Bogyo, M.; Basilion, J. P. *PLoS One* **2012**, *7*, e33060.

(10) Blum, G.; von Degenfeld, G.; Merchant, M. J.; Blau, H. M.; Bogyo, M. *Nat. Chem. Biol.* **2007**, *3*, 668-677.

4

5

6

7

8 9

10

11

15

17

21

24 25

26

27

31

35

36

37

39

41

43

44

45

46 47

48

49

51

53

54 55

59

60

(11)Blum, G.; Mullins, S. R.; Keren, K.; Fonovic, M.; Jedeszko, C.; Rice, M. J.; Sloane, B. F.; Bogyo, M. Nat. Chem. Biol. 2005, 1, 203-209. Rothberg, J. M.; Bailey, K. M.; Wojtkowiak, J. W.; Ben-Nun, Y.; Bogyo, M.; (12)Weber, E.; Moin, K.; Blum, G.; Mattingly, R. R.; Gillies, R. J.; Sloane, B. F. Neoplasia 2013, 15, 1125-1137. Weidle, U. H.; Tiefenthaler, G.; Georges, G. Cancer Genom. Proteom. 2014, 11, (13)67-80, 13 pp. Choi, K. Y.; Swierczewska, M.; Lee, S.; Chen, X. Theranostics 2012, 2, 156-178. (14)12 Vandooren, J.; Opdenakker, G.; Loadman, P. M.; Edwards, D. R. Adv. Drug (15)13 Delivery Rev. 2016, 97, 144-155. 14 (16)Joyce, J. A.; Baruch, A.; Chehade, K.; Meyer-Morse, N.; Giraudo, E.; Tsai, F.-Y.; Greenbaum, D. C.; Hager, J. H.; Bogyo, M.; Hanahan, D. Cancer Cell 2004, 5, 443-453. 16 (17)Bell-McGuinn, K. M.; Garfall, A. L.; Bogyo, M.; Hanahan, D.; Joyce, J. A. Cancer 18 Res. 2007, 67, 7378-7385. 19 Elie Benelita, T.; Gocheva, V.; Shree, T.; Dalrymple Stacie, A.; Holsinger Leslie, (18)20 J.; Joyce Johanna, A. Biochimie 2010, 92, 1618-1624. (19)Withana, N. P.; Blum, G.; Sameni, M.; Slaney, C.; Anbalagan, A.; Olive, M. B.; 22 Bidwell, B. N.; Edgington, L.; Wang, L.; Moin, K.; Sloane, B. F.; Anderson, R. L.; Bogyo, M. S.; 23 Parker, B. S. Cancer Res. 2012, 72, 1199-1209. (20)Shree, T.; Olson, O. C.; Elie, B. T.; Kester, J. C.; Garfall, A. L.; Simpson, K.; Bell-McGuinn, K. M.; Zabor, E. C.; Brogi, E.; Joyce, J. A. Gene. Dev. 2011, 25, 2465-2479. Mikhaylov, G.; Klimpel, D.; Schaschke, N.; Mikac, U.; Vizovisek, M.; Fonovic, (21)28 M.; Turk, V.; Turk, B.; Vasiljeva, O. Angew. Chem., Int. Ed. 2014, 53, 10077-10081. 29 Williams, C. B.; Yeh, E. S.; Soloff, A. C. Npj Breast Cancer 2016, 2, 15025. (22)30 Turner, D. Trans. Med. Chir. Soc. Edinb. 1903, 22, 43-46. (23)32 (24)Bonnett, R.; Berenbaum, M. Ciba Found. Symp. 1989, 146, 40-59. 33 Jori, G.; Photodynamic Therapy: Basic and Preclinical Aspects. In CRC Handbook (25)34 of Organic Photochemistry and Photobiology, CRC Press: 1995, 1379-1383. Dougherty, T. J.; Levy, J. G.; Mechanistic Principles of Photodynamic Therapy. In (26)CRC Handbook of Organic Photochemistry and Photobiology (2nd Edition), CRC Press LLC: **2004**, 147/141-147/117. 38 Henderson, B. W.; Gollnick, S. O.; Mechanistic Principles of Photodynamic (27)40 Therapy. In CRC Handbook of Organic Photochemistry and Photobiology (2nd Edition), CRC Press LLC: 2004, 145/141-145/125. 42 Castano, A. P.; Demidova, T. N.; Hamblin, M. R. Photodiagn. Photodyn. Ther. (28)2005, 2, 91-106. (29)Castano, A. P.; Demidova, T. N.; Hamblin, M. R. Photodiagn. Photodyn. Ther. 2005, 1, 279-293. (30)Castano, A. P.; Demidova, T. N.; Hamblin, M. R. Photodiagn. Photodyn. Ther. 2005, 2, 1-23. Josefsen, L. B.; Boyle, R. W. Met Based Drugs 2008, 2008, 276109. (31) 50 (32)Sessler, J. L.; Hemmi, G.; Mody, T. D.; Murai, T.; Burrell, A.; Young, S. W. Acc. Chem. Res. 1994, 27, 43-50. 52 Jung, H. S.; Han, J.; Shi, H.; Koo, S.; Singh, H.; Kim, H.-J.; Sessler, J. L.; Lee, J. (33)Y.; Kim, J.-H.; Kim, J. S. J. Am. Chem. Soc. 2017, 139, 7595-7602. 56 57 58

4

5

6

7

8

9

10

11

12

13

14

15

16 17

18

19

20

21

22

23

24 25

26

27

28

29

30

31 32

33

34

35

36

37

38

39

40

41

42

43

44

45

46 47

48

49

50

51

52

53

54 55

60

Mroz, P.; Sharma, S. K.; Zhiyentayev, T.; Huang, Y.-Y.; Hamblin, M. R. In Drug (34)Delivery in Oncology; Wiley-VCH Verlag GmbH & Co. KGaA: 2011, p 1569-1603. Ryan, F. D.; Paul, A. M.; David, W. Recent Pat. Drug Deliv. Formul. 2009, 3, 1-7. (35)(36) Calixto, G. M. F.; Bernegossi, J.; Marise de Freitas, L.; Fontana, C. R.; Chorilli, M. *Molecules* **2016**, *21*, 42/41-42/18. Moret, F.; Reddi, E. J. Porphyrins Phthalocyanines 2017, 21, 239-256. (37) Heinemann, F.; Karges, J.; Gasser, G. Acc. Chem. Res. 2017, 50, 2727-2736. (38)Clarke, M. J. Coord. Chem. Rev. 2003, 236, 209-233. (39) Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Met. Ions Biol. Syst. 2004, 42, (40)323-351. (41)Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, B. K. J. Inorg. Biochem. 2006, 100, 891-904. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Curr. Top. Med. Chem. 2004, 4, (42) 1525-1535. Lee, J.; Udugamasooriya, D. G.; Lim, H.-S.; Kodadek, T. Nat. Chem. Biol. 2010, (43) 6, 258-260. Allison, R. R.; Downie, G. H.; Cuenca, R.; Hu, X.-H.; Childs, C. J. H.; Sibata, C. (44)H. Photodiagn. Photodyn. Ther. 2004, 1, 27-42. (45) Howerton, B. S.; Heidary, D. K.; Glazer, E. C. J. Am. Chem. Soc. 2012, 134, 8324-8327. Smith, N. A.; Sadler, P. J. Philos. Trans. A Mat. Phys. Eng. Sci. 2013, 371, (46)20120519/20120511-20120519/20120513. Schatzschneider, U. Eur. J. Inorg. Chem. 2010, 1451-1467. (47)Frei, A.; Rubbiani, R.; Tubafard, S.; Blacque, O.; Anstaett, P.; Felgentrager, A.; (48)Maisch, T.; Spiccia, L.; Gasser, G. J. Med. Chem. 2014, 57, 7280-7292. Arenas, Y.; Monro, S.; Shi, G.; Mandel, A.; McFarland, S.; Lilge, L. Photodiagn. (49) Photodyn. Ther. 2013, 10, 615-625. Fong, J.; Kasimova, K.; Arenas, Y.; Kaspler, P.; Lazic, S.; Mandel, A.; Lilge, L. (50)Photochem. Photobiol. Sci. 2015, 14, 2014-2023. Kaspler, P.; Lazic, S.; Forward, S.; Arenas, Y.; Mandel, A.; Lilge, L. Photochem. (51)Photobiol. Sci. 2016, 15, 481-495. Puckett, C. A.; Ernst, R. J.; Barton, J. K. Dalton Trans. 2010, 39, 1159-1170. (52) (53) Puckett, C. A.; Barton, J. K. Biochemistry 2008, 47, 11711-11716. Mulcahy, S. P.; Li, S.; Korn, R.; Xie, X.; Meggers, E. Inorg. Chem. 2008, 47, 5030-(54)5032. (55)Meggers, E. Chem. Commun. 2009, 1001-1010. (56) Respondek, T.; Sharma, R.; Herroon, M. K.; Garner, R. N.; Knoll, J. D.; Cueny, E.; Turro, C.; Podgorski, I.; Kodanko, J. J. ChemMedChem 2014, 9, 1306-1315. (57) Ramalho Suelem, D.; Vieira Paulo, C.; Sharma, R.; Kodanko Jeremy, J.; White Jessica, K.; Turro, C.; Aggarwal, N.; Chalasani, A.; Sameni, M.; Moin, K.; Sloane Bonnie, F.; Moin, K.; Sloane Bonnie, F. PLoS One 2015, 10, e0142527. (58)Knoll, J. D.; Albani, B. A.; Turro, C. Chem. Commun. 2015, 51, 8777-8780. (59) Knoll, J. D.; Albani, B. A.; Turro, C. Acc. Chem. Res. 2015, 48, 2280-2287. Towatari, T.; Nikawa, T.; Murata, M.; Yokoo, C.; Tamai, M.; Hanada, K.; (60)Katunuma, N. FEBS Lett. 1991, 280, 311-315. Stern, I.; Schaschke, N.; Moroder, L.; Turk, D. Biochem. J. 2004, 381, 511-517. (61)

(62) Montalti, M.; Credi, A.; Prodi, L.; Gandolfi, M. T. Handbook of Photochemistry;
3rd ed.; CRC Press: Boca Raton, FL, 2006.
(63) Bhattacharyya, K.; Das, P. K. Chem. Phys. Lett. <b>1985</b> , 116, 326-332.
(64) Nakamaru, K. Bull. Chem. Soc. Jpn. <b>1982</b> , 55, 2697-2705.
(65) Huisman, M.; White, J. K.; Lewalski, V. G.; Podgorski, I.; Turro, C.; Kodanko, J.
J. Chem. Commun. 2016, 52, 12590-12593.
(66) Jedeszko, C.; Sameni, M.; Olive, M. B.; Moin, K.; Sloane, B. F. Curr. Protoc. Cell
<i>Biol.</i> 2008, <i>39</i> , 4.20.1-420.15.
(67) Podgorski, I.; Linebaugh, B. E.; Sameni, M.; Jedeszko, C.; Bhagat, S.; Cher, M. L.;
Sloane, B. F. <i>Neoplasia</i> <b>2005</b> , <i>7</i> , 207-223.
(68) Sameni, M.: Dosescu, J.: Moin, K.: Sloane, B. F. <i>Mol. Imaging</i> <b>2003</b> , <i>2</i> , 159-175.
(69) Aggarwal, N.: Sloane, B. F. Proteomics: Clin Appl 2014, 8, 427-437.
(70) Roshy S : Sloane B F : Moin K Cancer Metastasis Rev 2003 22 271-286
(70) Turk V : Stoka V : Vasilieva O : Renko M : Sun T : Turk B : Turk D <i>Riochim</i>
Riophys Acta Proteomics 2012 1824 68-88
$(72) \qquad \text{Montaser M \cdot I almanach } G \cdot \text{Mach I } Riol Cham 2002 383 1305-1308$
(72) Schiefer I T · Tanadar S · Litosh V · Siklos M · Soism D · Wijawiakroma G
T. Chandrasena E. D. Sinha V. Tavassoli E. Brunsteiner M. E. M. Arancio O. Detukhov
D: Thatabar C D I I Mad Cham 2013 56 6054 6069
1., Hawner, U. K. J. J. Well. Chem. 2013, JU, 0034-0000. (74) Longr Cohomes, A. Cladare, D. Sarahar, I. D. Longr Alvaredo, D. Downer, M.
(14) Lopez-Cobenas, A.; Cleuera, F.; Sanchez, J. D.; Lopez-Alvarado, P.; Ramos, M. T. Avandona, C. Monandaz, I. C. Sunthania 2005, 2412, 2422
1.; Avendano, U.; Menendez, J. U. Synthesis 2005, 3412-3422.
(75) Snarma, K.; Knoll, J. D.; Ancona, N.; Martin, P. D.; Turro, C.; Kodanko, J. J. <i>Inorg.</i>
Cnem. 2013, 34, 1901-1911.
(/b) Huisman, M.; Kodanko, J.; Arora, K.; Herroon, M. K.; Alnaed, M.; Endicott, J. F.;
Podgorski, I.; Kodanko, J. J. Inorg. Chem. 2018, 57, 7881-7891.
(77) Lameijer, L. N.; Hopkins, S. L.; Breve, T. G.; Askes, S. H. C.; Bonnet, S. Chem
<i>Eur. J.</i> <b>2016</b> , <i>22</i> , 18484-18491.
(78) Bahreman, A.; Limburg, B.; Siegler, M. A.; Bouwman, E.; Bonnet, S. <i>Inorg. Chem.</i>
<b>2013</b> , <i>52</i> , 9456-9469.
(79) Li, A.; Yadav, R.; White, J. K.; Herroon, M. K.; Callahan, B. P.; Podgorski, I.;
Turro, C.; Scott, E. E.; Kodanko, J. J. Chem. Commun. 2017, 53, 3673-3676.
(80) Huisman, M.; Lewalski, V. G.; Kodanko, J. J.; White, J. K.; Turro, C.; Podgorski,
I. Chem. Commun. 2016, 52, 12590-12593.
(81) Poynton, F. E.; Bright, S. A.; Blasco, S.; Williams, D. C.; Kelly, J. M.;
Gunnlaugsson, T. Chem. Soc. Rev. 2017, 46, 7706-7756.
(82) Pierroz, V.; Joshi, T.; Leonidova, A.; Mari, C.; Schur, J.: Ott. I.: Spiccia. L.: Ferrari.
S.: Gasser, G. J. Am. Chem. Soc. 2012, 134, 20376-20387.
(83) Huang, H.: Zhang, P.: Yu, B.: Chen, Y.: Wang, I.: Ii, L.: Chao, H. J. Med. Chem
<b>2014</b> . 57. 8971-8983.
(84) Chrzanowska M · Katafias A · Impert O · Kozakiewicz A · Surdykowski A ·
Brzozowska P · Franke A · Zahl A · Puchta R · van Fldik R Dalton Trans 2017 16 10264
10200 worka, 1., 11anke, A., Zani, A., 1 uenta, K., van Eluik, K. Danon 11ans. 2017, 40, 10204-
10200. (85) Maguruk O. Magiana K. Dug D. Sugarat E. Kinda C. Drindall M. I. Dial.
(0.5) Widzuryk, U.; Widgiera, K.; Kys, B.; Suzenet, F.; Kieda, U.; Brindell, M. J. Biol. Linewa Cham <b>2014</b> 10 1205 1216
11101 g. Uneill. 2014, 19, 1303-1310. (86) Lomoiton Lucion N. Honking Somenthe L. Drevé Tabias C. Ashas Source H. C.
Cooj Lamenjer Lucien, N., Hopkins Samanuna, L.; Breve Tobias, G.; Askes Sven, H. C.; Donnot S. Chem. Fug. J. 2016, 22, 19494, 19401
Domici, S. Cheill. Eur. J. 2010, 22, 18484-18491.
45 ACS Daragon Dive Fourier and
ACS Paragon Plus Environment

(87)Powers, J. C.; Asgian, J. L.; Ekici, O. D.; James, K. E. Chem. Rev. 2002, 102, 4639-4750. Turk, B. Nat. Rev. Drug Discov. 2006, 5, 785-799. (88)(89) Otto, H.-H.; Schirmeister, T. Chem Rev 1997, 97, 133-172. Frlan, R.; Gobec, S. Curr. Med. Chem. 2006, 13, 2309-2327. (90)Strelow, J. M. SLAS Discovery 2017, 22, 3-20. (91) Lovitt, C. J.; Shelper, T. B.; Avery, V. M. Assay Drug Devel. Technol. 2013, 11, (92) 435-448. (93) Elliott, N. T.; Yuan, F. J. Pharm. Sci. 2011, 100, 59-74. Lovitt, C. J.; Shelper, T. B.; Avery, V. M. J. Cancer Res. Clin. Oncol. 2015, 141, (94)951-959. Herroon Mackenzie, K.; Sharma, R.; Rajagurubandara, E.; Turro, C.; Kodanko (95) Jeremy, J.; Podgorski, I. Biol. Chem. 2016, 397, 571-582. (96) Sharma, R.; Knoll, J. D.; Martin, P. D.; Podgorski, I.; Turro, C.; Kodanko, J. J. Inorg. Chem. 2014, 53, 3272-3274. Respondek, T.; Garner, R. N.; Herroon, M. K.; Podgorski, I.; Turro, C.; Kodanko, (97) J. J. J. Am. Chem. Soc. 2011, 133, 17164-17167. Damrauer, N. H.; Cerullo, G.; Yeh, A.; Boussie, T. R.; Shank, C. V.; McCusker, J. (98) K. Science 1997, 275, 54. (99) Arosio, D.; Casagrande, C. Adv. Drug Delivery Rev. 2016, 97, 111-143. (100) Marchetti, C.; Palaia, I.; Giorgini, M.; De Medici, C.; Iadarola, R.; Vertechy, L.; Domenici, L.; Di Donato, V.; Tomao, F.; Muzii, L.; Panici, P. B. OncoTargets Ther. 2014, 7, 1223-1236. (101) Cukierman, E.; Khan, D. R. Biochem. Pharmacol. 2010, 80, 762-770. (102) Malam, Y.; Loizidou, M.; Seifalian, A. M. Trends Pharmacol. Sci. 2009, 30, 592-599. (103) Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nat. Nanotechnol. 2007. 2, 751-760. (104) Shadidi, M.; Sioud, M. Drug Resist. Updates 2004, 6, 363-371. (105) Ben-Nun, Y.; Merquiol, E.; Brandis, A.; Turk, B.; Scherz, A.; Blum, G. Theranostics 2015, 5, 847-862. (106) MacDonald Ian, J.; Morgan, J.; Bellnier David, A.; Paszkiewicz Geraldine, M. L.; Whitaker James, E.; Litchfield Debra, J.; Dougherty Thomas, J. Photochem. Photobiol. 2008, 70, 789-797. (107) Zuluaga, M.-F.; Sekkat, N.; Gabriel, D.; van den Bergh, H.; Lange, N. Mol. Cancer Ther. 2013, 12, 306-313. (108) Li, S.-Y.; Cheng, H.; Qiu, W.-X.; Liu, L.-H.; Chen, S.; Hu, Y.; Xie, B.-R.; Li, B.; Zhang, X.-Z. ACS Appl. Mater. Interfaces 2015, 7, 28319-28329. (109) Mullins, S. R.; Sameni, M.; Blum, G.; Bogyo, M.; Sloane, B. F.; Moin, K. Biol. Chem. 2012, 393, 1405-1416. (110) Akinboye, E. S.; Rosen, M. D.; Bakare, O.; Denmeade, S. R. Bioorg. Med. Chem. **2017**, *25*, 6707-6717. (111) Gabriel, D.; Zuluaga, M. F.; Martinez, M. N.; Campo, M. A.; Lange, N. J. Drug Delivery Sci. Technol. 2009, 19, 15-24. (112) Tauro, J. R.; Lee, B.-S.; Lateef, S. S.; Gemeinhart, R. A. Peptides 2008, 29, 1965-1973.

(113) Warnecke, A.; Fichtner, I.; Sass, G.; Kratz, F. Arch. Pharm. 2007, 340, 389-395.

(114) de Groot, F. M. H.; Broxterman, H. J.; Adams, H. P. H. M.; van Vliet, A.; Tesser,

G. I.; Elderkamp, Y. W.; Schraa, A. J.; Kok, R. J.; Molema, G.; Pinedo, H. M.; Scheeren, H. W. *Mol. Cancer Ther.* **2002**, *1*, 901-911.

(115) Zsebik, B.; Symonowicz, K.; Saleh, Y.; Ziolkowski, P.; Bronowicz, A.; Vereb, G. *Cell Proliferation* **2007**, *40*, 38-49.

(116) Aggarwal, N.; Santiago, A. M.; Kessel, D.; Sloane, B. F. *Breast Cancer Res. Treat.* **2015**, *154*, 251-262.

(117) Saneesh Babu, P. S.; Manu, P. M.; Dhanya, T. J.; Tapas, P.; Meera, R. N.; Surendran, A.; Aneesh, K. A.; Vadakkancheril, S. J.; Ramaiah, D.; Nair, S. A.; Pillai, M. R. *Sci. Reports* **2017**, *7*, 42126.

(118) Nguyen, P. L.; Taghian, A. G.; Katz, M. S.; Niemierko, A.; Abi Raad, R. F.; Boon, W. L.; Bellon, J. R.; Wong, J. S.; Smith, B. L.; Harris, J. R. *J. Clinical Oncol.* **2008**, *26*, 2373-2378.

# TOC Graphic

